비뇨생식기계 의약품 시장 : 규모, 점유율, 성장, 산업 분석, 지역 인사이트 및 예측(2026-2034년)

Growth Factors of genitourinary drugs Market

The global genitourinary drugs market size was valued at USD 28.70 billion in 2025 and is projected to grow from USD 30.10 billion in 2026 to USD 44.40 billion by 2034, exhibiting a CAGR of 4.98% during the forecast period. North America dominated the market with a 38.08% share in 2025, supported by high diagnosis rates, advanced healthcare infrastructure, and widespread access to innovative therapies.

Genitourinary drugs are used to treat disorders affecting the urinary and reproductive systems, including benign prostatic hyperplasia (BPH), erectile dysfunction, overactive bladder (OAB), urinary tract infections (UTIs), prostate cancer, bladder cancer, and urinary incontinence. Growing prevalence of these disorders, combined with an aging population and increasing healthcare awareness, continues to drive market expansion worldwide.

Key Market Trend

Expansion of Specialty Drugs for Urologic Oncology

One of the most significant trends shaping the genitourinary drugs market is the growing adoption of specialty drugs for bladder, kidney, and prostate cancers. Pharmaceutical companies are investing heavily in immunotherapies, antibody-drug conjugates, and localized drug-delivery systems designed to improve survival rates and treatment outcomes.

In March 2026, Johnson & Johnson announced positive results for Erda-iDRS, an investigational intravesical drug-releasing system utilizing erdafitinib for bladder cancer treatment. Such innovations highlight the industry's transition toward more specialized and targeted oncology therapies.

Market Drivers

Rising Prevalence of Urinary and Reproductive Disorders

The increasing incidence of urinary tract disorders and reproductive health conditions remains a primary growth driver. Conditions such as BPH, erectile dysfunction, prostate cancer, and bladder disorders are becoming more common, particularly among aging populations.

In June 2025, Bayer AG received FDA approval for NUBEQA (darolutamide) for metastatic hormone-sensitive prostate cancer, expanding treatment access and reinforcing demand for advanced genitourinary therapies.

Market Restraints

Side Effects and Poor Drug Tolerability

Many genitourinary drugs are associated with adverse effects such as dizziness, constipation, dry mouth, cognitive impairment, and sexual dysfunction. These side effects often reduce patient compliance and long-term treatment adherence.

As a result, treatment discontinuation rates remain a challenge for pharmaceutical companies seeking sustained prescription growth.

Market Opportunities

Development of Novel Drug-Delivery Technologies

Innovative drug-delivery platforms are creating substantial opportunities across the market. Sustained-release formulations and intravesical therapies improve drug exposure at disease sites while enhancing patient convenience.

For example, UroGen Pharma's UGN-102 utilizes RTGel sustained-release technology to treat non-muscle-invasive bladder cancer, demonstrating how advanced delivery systems can improve clinical outcomes and expand treatment adoption.

Market Challenges

Pricing and Reimbursement Issues

Advanced therapies, particularly in oncology, often carry premium pricing that can limit accessibility. Delays in reimbursement approvals and funding restrictions create barriers to widespread adoption.

Healthcare systems increasingly face challenges balancing affordability with access to innovative treatments, especially in prostate and bladder cancer therapies.

Segment Analysis

By Drug Class

The PDE5 inhibitors segment dominated the market in 2025 due to widespread use in erectile dysfunction treatment. Established products and high patient acceptance continue to support segment leadership.

The beta-3 adrenergic agonists segment is expected to register the fastest growth during the forecast period.

By Disease Indication

The Benign Prostatic Hyperplasia (BPH) segment accounted for the largest market share in 2025. Long-term treatment requirements and growing prevalence among aging men contribute significantly to demand.

The bladder/urothelial cancer segment is projected to witness strong growth due to increasing adoption of targeted therapies.

By Age Group

The adult segment held the largest share in 2025 because most genitourinary disorders are diagnosed and treated within adult populations.

By Type

Branded drugs dominated the market owing to their innovative mechanisms, premium pricing, and strong clinical differentiation, particularly in oncology.

By Route of Administration

The oral segment captured the largest share due to ease of administration, patient convenience, and suitability for chronic disease management.

By Gender

The male segment dominated the market because of the high prevalence of prostate cancer, erectile dysfunction, and BPH.

By Distribution Channel

Drug stores and retail pharmacies represented the leading distribution channel due to their accessibility and role in dispensing long-term outpatient therapies.

Regional Analysis

North America

North America remained the leading regional market, reaching USD 10.93 billion in 2025. Strong healthcare infrastructure, high disease awareness, and rapid adoption of innovative treatments continue to support regional growth.

Europe

Europe is expected to experience steady growth due to its aging population and increasing burden of chronic genitourinary disorders.

Asia Pacific

Asia Pacific is emerging as a high-growth region driven by improving healthcare access, rising healthcare expenditures, and expanding patient populations in countries such as China, India, and Japan.

Latin America and Middle East & Africa

These regions are expected to witness moderate growth supported by increasing awareness, healthcare modernization, and expanding access to treatment options.

Competitive Landscape

Major companies operating in the genitourinary drugs market include:

• Astellas Pharma Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Johnson & Johnson
• Bayer AG
• AstraZeneca PLC
• Organon & Co.
• Ferring Pharmaceuticals

These companies are focusing on product innovation, regulatory approvals, strategic partnerships, and oncology-focused research to strengthen their market positions.

Recent Industry Developments

• March 2026: UroGen Pharma announced progress toward the commercial launch of ZUSDURI for recurrent bladder cancer.
• February 2026: Organon partnered with Sebela Pharmaceuticals for rights to MIUDELLA, a hormone-free copper IUD.
• November 2025: Pfizer received FDA approval for PADCEV combined with Keytruda for muscle-invasive bladder cancer treatment.
• June 2025: Knight Therapeutics partnered with Sumitomo Pharma America to commercialize multiple genitourinary therapies in Canada.
• March 2025: GSK received FDA approval for Blujepa (gepotidacin) for uncomplicated urinary tract infections.

Conclusion

The global genitourinary drugs market is positioned for steady growth through 2034, supported by rising prevalence of urinary and reproductive disorders, expanding aging populations, and increasing adoption of targeted therapies. Advances in specialty oncology drugs, innovative drug-delivery technologies, and broader treatment accessibility are expected to reshape the competitive landscape. Despite challenges related to drug tolerability, pricing, and reimbursement, ongoing pharmaceutical innovation and growing healthcare investments will continue to create significant opportunities for market participants throughout the forecast period.

Segmentation By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Region

By Drug Class * Androgen Receptor Pathway Inhibitors

• GnRH Agonists/GnRH Antagonists
• PDE5 Inhibitors
• Alpha Blockers
• Antimuscarinics/Anticholinergics
• Beta-3 Adrenergic Agonists
• Others

By Disease Indication * Prostate Cancer

• Benign Prostatic Hyperplasia (BPH)
• Erectile Dysfunction
• Overactive Bladder (OAB)
• Urinary Tract Infections (UTIs)
• Bladder/Urothelial Cancer
• Others

By Age Group * Pediatric

• Adult
• Geriatric

By Type * Branded

• Generics

By Route of Administration * Oral

• Vaginal
• Injectable/Parenteral
• Topical/Transdermal
• Others

By Gender * Male

• Female

By Distribution Channel * Hospital Pharmacies

• Drug Stores & Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

By Region * North America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Genitourinary Disease Indications, By Key Regions/ Countries
• 4.2. New Product Launches, By Key Players
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Overview of Regulatory Scenario, By Key Regions/ Countries
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)

5. Global Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Androgen Receptor Pathway Inhibitors
  • 5.1.2. GnRH Agonists/GnRH Antagonists
  • 5.1.3. PDE5 Inhibitors
  • 5.1.4. Alpha Blockers
  • 5.1.5. Antimuscarinics/Anticholinergics
  • 5.1.6. Beta-3 Adrenergic Agonists
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Prostate Cancer
  • 5.2.2. Benign Prostatic Hyperplasia (BPH)
  • 5.2.3. Erectile Dysfunction
  • 5.2.4. Overactive Bladder (OAB)
  • 5.2.5. Urinary Tract Infections (UTIs)
  • 5.2.6. Bladder/Urothelial Cancer
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adult
  • 5.3.3. Geriatric
• 5.4. Market Analysis, Insights and Forecast - By Type
  • 5.4.1. Branded
  • 5.4.2. Generics
• 5.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.5.1. Oral
  • 5.5.2. Vaginal
  • 5.5.3. Injectable/Parenteral
  • 5.5.4. Topical/Transdermal
  • 5.5.5. Others
• 5.6. Market Analysis, Insights and Forecast - By Gender
  • 5.6.1. Male
  • 5.6.2. Female
• 5.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.7.1. Hospital Pharmacies
  • 5.7.2. Drug Stores & Retail Pharmacies
  • 5.7.3. Online Pharmacies
  • 5.7.4. Specialty Pharmacies
• 5.8. Market Analysis, Insights and Forecast - Region
  • 5.8.1. North America
  • 5.8.2. Europe
  • 5.8.3. Asia Pacific
  • 5.8.4. Latin America
  • 5.8.5. Middle East & Africa

6. North America Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Androgen Receptor Pathway Inhibitors
  • 6.1.2. GnRH Agonists/GnRH Antagonists
  • 6.1.3. PDE5 Inhibitors
  • 6.1.4. Alpha Blockers
  • 6.1.5. Antimuscarinics/Anticholinergics
  • 6.1.6. Beta-3 Adrenergic Agonists
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Prostate Cancer
  • 6.2.2. Benign Prostatic Hyperplasia (BPH)
  • 6.2.3. Erectile Dysfunction
  • 6.2.4. Overactive Bladder (OAB)
  • 6.2.5. Urinary Tract Infections (UTIs)
  • 6.2.6. Bladder/Urothelial Cancer
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adult
  • 6.3.3. Geriatric
• 6.4. Market Analysis, Insights and Forecast - By Type
  • 6.4.1. Branded
  • 6.4.2. Generics
• 6.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.5.1. Oral
  • 6.5.2. Vaginal
  • 6.5.3. Injectable/Parenteral
  • 6.5.4. Topical/Transdermal
  • 6.5.5. Others
• 6.6. Market Analysis, Insights and Forecast - By Gender
  • 6.6.1. Male
  • 6.6.2. Female
• 6.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.7.1. Hospital Pharmacies
  • 6.7.2. Drug Stores & Retail Pharmacies
  • 6.7.3. Online Pharmacies
  • 6.7.4. Specialty Pharmacies
• 6.8. Market Analysis, Insights and Forecast - By Country
  • 6.8.1. U.S.
  • 6.8.2. Canada

7. Europe Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Androgen Receptor Pathway Inhibitors
  • 7.1.2. GnRH Agonists/GnRH Antagonists
  • 7.1.3. PDE5 Inhibitors
  • 7.1.4. Alpha Blockers
  • 7.1.5. Antimuscarinics/Anticholinergics
  • 7.1.6. Beta-3 Adrenergic Agonists
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Prostate Cancer
  • 7.2.2. Benign Prostatic Hyperplasia (BPH)
  • 7.2.3. Erectile Dysfunction
  • 7.2.4. Overactive Bladder (OAB)
  • 7.2.5. Urinary Tract Infections (UTIs)
  • 7.2.6. Bladder/Urothelial Cancer
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adult
  • 7.3.3. Geriatric
• 7.4. Market Analysis, Insights and Forecast - By Type
  • 7.4.1. Branded
  • 7.4.2. Generics
• 7.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.5.1. Oral
  • 7.5.2. Vaginal
  • 7.5.3. Injectable/Parenteral
  • 7.5.4. Topical/Transdermal
  • 7.5.5. Others
• 7.6. Market Analysis, Insights and Forecast - By Gender
  • 7.6.1. Male
  • 7.6.2. Female
• 7.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.7.1. Hospital Pharmacies
  • 7.7.2. Drug Stores & Retail Pharmacies
  • 7.7.3. Online Pharmacies
  • 7.7.4. Specialty Pharmacies
• 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.8.1. U.K.
  • 7.8.2. Germany
  • 7.8.3. France
  • 7.8.4. Italy
  • 7.8.5. Spain
  • 7.8.6. Scandinavia
  • 7.8.7. Rest of Europe

8. Asia Pacific Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Androgen Receptor Pathway Inhibitors
  • 8.1.2. GnRH Agonists/GnRH Antagonists
  • 8.1.3. PDE5 Inhibitors
  • 8.1.4. Alpha Blockers
  • 8.1.5. Antimuscarinics/Anticholinergics
  • 8.1.6. Beta-3 Adrenergic Agonists
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Prostate Cancer
  • 8.2.2. Benign Prostatic Hyperplasia (BPH)
  • 8.2.3. Erectile Dysfunction
  • 8.2.4. Overactive Bladder (OAB)
  • 8.2.5. Urinary Tract Infections (UTIs)
  • 8.2.6. Bladder/Urothelial Cancer
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adult
  • 8.3.3. Geriatric
• 8.4. Market Analysis, Insights and Forecast - By Type
  • 8.4.1. Branded
  • 8.4.2. Generics
• 8.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.5.1. Oral
  • 8.5.2. Vaginal
  • 8.5.3. Injectable/Parenteral
  • 8.5.4. Topical/Transdermal
  • 8.5.5. Others
• 8.6. Market Analysis, Insights and Forecast - By Gender
  • 8.6.1. Male
  • 8.6.2. Female
• 8.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.7.1. Hospital Pharmacies
  • 8.7.2. Drug Stores & Retail Pharmacies
  • 8.7.3. Online Pharmacies
  • 8.7.4. Specialty Pharmacies
• 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.8.1. China
  • 8.8.2. Japan
  • 8.8.3. India
  • 8.8.4. Southeast Asia
  • 8.8.5. Australia
  • 8.8.6. Rest of Asia Pacific

9. Latin America Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Androgen Receptor Pathway Inhibitors
  • 9.1.2. GnRH Agonists/GnRH Antagonists
  • 9.1.3. PDE5 Inhibitors
  • 9.1.4. Alpha Blockers
  • 9.1.5. Antimuscarinics/Anticholinergics
  • 9.1.6. Beta-3 Adrenergic Agonists
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Prostate Cancer
  • 9.2.2. Benign Prostatic Hyperplasia (BPH)
  • 9.2.3. Erectile Dysfunction
  • 9.2.4. Overactive Bladder (OAB)
  • 9.2.5. Urinary Tract Infections (UTIs)
  • 9.2.6. Bladder/Urothelial Cancer
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adult
  • 9.3.3. Geriatric
• 9.4. Market Analysis, Insights and Forecast - By Type
  • 9.4.1. Branded
  • 9.4.2. Generics
• 9.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.5.1. Oral
  • 9.5.2. Vaginal
  • 9.5.3. Injectable/Parenteral
  • 9.5.4. Topical/Transdermal
  • 9.5.5. Others
• 9.6. Market Analysis, Insights and Forecast - By Gender
  • 9.6.1. Male
  • 9.6.2. Female
• 9.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.7.1. Hospital Pharmacies
  • 9.7.2. Drug Stores & Retail Pharmacies
  • 9.7.3. Online Pharmacies
  • 9.7.4. Specialty Pharmacies
• 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.8.1. Brazil
  • 9.8.2. Mexico
  • 9.8.3. Rest of Latin America

10. Middle East & Africa Genitourinary Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Androgen Receptor Pathway Inhibitors
  • 10.1.2. GnRH Agonists/GnRH Antagonists
  • 10.1.3. PDE5 Inhibitors
  • 10.1.4. Alpha Blockers
  • 10.1.5. Antimuscarinics/Anticholinergics
  • 10.1.6. Beta-3 Adrenergic Agonists
  • 10.1.7. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Prostate Cancer
  • 10.2.2. Benign Prostatic Hyperplasia (BPH)
  • 10.2.3. Erectile Dysfunction
  • 10.2.4. Overactive Bladder (OAB)
  • 10.2.5. Urinary Tract Infections (UTIs)
  • 10.2.6. Bladder/Urothelial Cancer
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adult
  • 10.3.3. Geriatric
• 10.4. Market Analysis, Insights and Forecast - By Type
  • 10.4.1. Branded
  • 10.4.2. Generics
• 10.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.5.1. Oral
  • 10.5.2. Vaginal
  • 10.5.3. Injectable/Parenteral
  • 10.5.4. Topical/Transdermal
  • 10.5.5. Others
• 10.6. Market Analysis, Insights and Forecast - By Gender
  • 10.6.1. Male
  • 10.6.2. Female
• 10.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.7.1. Hospital Pharmacies
  • 10.7.2. Drug Stores & Retail Pharmacies
  • 10.7.3. Online Pharmacies
  • 10.7.4. Specialty Pharmacies
• 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.8.1. GCC
  • 10.8.2. South Africa
  • 10.8.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Astellas Pharma Inc.
  • 11.2.2. Pfizer Inc.
  • 11.2.3. Merck & Co., Inc.
  • 11.2.4. Johnson & Johnson
  • 11.2.5. Bayer AG
  • 11.2.6. AstraZeneca PLC
  • 11.2.7. Sumitomo Pharma Co., Ltd.
  • 11.2.8. Organon & Co.
  • 11.2.9. Ferring Pharmaceuticals
  • 11.2.10. Endo, Inc.